Active substance isatuximab
Holder Sanofi Belgium
Status Running
Indication in combination with pomalidomide and dexamethasone (Isa-Pd) for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy
Public documents  Approbation
  Information for the patient
  Informed consent
Last update 15/10/2021


Last updated on 17/11/2021